PS 13-10 INDUCTION OF ANGIOGENESIS BY A TYPE III PHOSPHODIESTERASE INHIBITOR THROUGH ACTIVATION OF PPAR GAMMA AND cAMP PATHWAYS

Objective: Peripheral arterial disease (PAD) is highly prevalent in the elderly as well as in the subjects with cardiovascular risk factors such as diabetes. Approximately 2–4% of those affected with PAD commonly complain of intermittent claudication (IC). Cilostazol, a type III phosphodiesterase inhibitor, is the only FDA-approved drug for the treatment of… (More)